Patient Experience with the SensoReady

Medication delivery device design impacts treatment satisfaction, adherence, and compliance in patients receiving biologics. This survey assessed autoinjector attributes that are important to patients, and assessed patient perceptions and preferences between an adalimumab biosimilar autoinjector (Hyrimoz In this survey, adult patients were recruited for web-assisted telephone interviews. Patients had ≥ 3 months' experience with the ref-ADL pen and 1-12 months' experience with the SDZ-ADL pen. The survey included 120 patients with RA (n = 32) or CD (n = 88). Mean experience with the ref-ADL pen was 7 years for RA or 5 years for CD vs 9 months with the SDZ-ADL pen. The most important autoinjector attributes were the ability to use the pen independently and the ease and simplicity of self-injection. When comparing the two autoinjectors, patients significantly preferred the SDZ-ADL pen over the ref-ADL pen for nearly every attribute evaluated, with the greatest differences reported for visual and audible feedback mechanisms, ease of self-injection, and ability to use the device independently. Overall, 82% of patients preferred the SDZ-ADL pen over the ref-ADL pen, with buttonless activation and less injection pain being the main drivers for this preference. Patients with RA or CD indicated a preference for the SDZ-ADL pen over the ref-ADL pen, independent of the duration of use of the pen. The preference for a biosimilar device within 1 year of switching provides reassurance of rapid patient acceptance of biosimilars and may simplify the switching process. These results confirm the importance of ensuring autoinjector design supports independent self-administration of medication and align with previous data showing high patient satisfaction with the SDZ-ADL pen.

Informations de copyright

© 2024 Jathanakodi et al.

Déclaration de conflit d'intérêts

Shrihari Jathanakodi and Charlotte Both were employees of Sandoz Group AG. Ines Brueckmann is an employee of Sandoz Group AG. Laura Rose is an employee of Sandoz Inc. Nahal Nasseri is an employee of Sandoz Canada Inc. Jean-Pierre Raynauld has been a speaker or advisor for AbbVie, Amgen, BIOJAMP, Janssen, Novartis, Organon, Orimed, Pfizer, Sandoz, Sanofi, and UCB. Neeraj Narula has been a speaker or advisor for AbbVie, Bristol Myers Squibb, Eli Lilly, Ferring, Fresenius Kabi, Innomar Strategies, Iterative Health, Janssen, Merck, Pfizer, Sandoz, Takeda, and Viatris. The authors report no other conflicts of interest in this work.